Cargando…

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals

Although hepatitis C virus (HCV) RNA may be eliminated from blood circulation by direct-acting antivirals (DAA) therapy as assessed by real-time polymerase chain reaction (PCR), HCV RNA can still be present in liver tissue, and this is known as occult HCV. There has been a lot of controversy surroun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kishta, Sara, Tabll, Ashraf, Omanovic Kolaric, Tea, Smolic, Robert, Smolic, Martina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344618/ https://www.ncbi.nlm.nih.gov/pubmed/32630610 http://dx.doi.org/10.3390/biomedicines8060175

Ejemplares similares

Mechanisms of Hepatic Cholestatic Drug Injury
por: Kolarić, Tea Omanović, et al.
Publicado: (2019)

Renoprotective Effect of Liraglutide Is Mediated via the Inhibition of TGF-Beta 1 in an LLC-PK1 Cell Model of Diabetic Nephropathy
por: Ninčević, Vjera, et al.
Publicado: (2022)

The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD
por: Petrovic, Ana, et al.
Publicado: (2023)

An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents
por: Rupcic Rubin, Vinka, et al.
Publicado: (2021)

The role of direct oral anticoagulants in the era of COVID-19: are antiviral therapy and pharmacogenetics limiting factors?
por: Roguljić, Hrvoje, et al.
Publicado: (2022)

Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes
por: Ninčević, Vjera, et al.
Publicado: (2019)

MicroRNAs: Small Molecules with Significant Functions, Particularly in the Context of Viral Hepatitis B and C Infection
por: Megahed, Fayed, et al.
Publicado: (2023)

Pretreatment of Garlic Oil Extracts Hampers Epithelial Damage in Cell Culture Model of Peptic Ulcer Disease
por: Kuna, Lucija, et al.
Publicado: (2022)

Liraglutide Exerts Protective Effects by Downregulation of PPARγ, ACSL1 and SREBP-1c in Huh7 Cell Culture Models of Non-Alcoholic Steatosis and Drug-Induced Steatosis
por: Omanovic Kolaric, Tea, et al.
Publicado: (2022)

Molecular Mechanisms Linking Empagliflozin to Renal Protection in the LLC-PK1 Model of Diabetic Nephropathy
por: Mihaljević, Vjera, et al.
Publicado: (2022)

Targeting the Wnt Signaling Pathway in Liver Fibrosis for Drug Options: An Update
por: Duspara, Kristina, et al.
Publicado: (2021)

Primary Care Provider Counseling Practices about Adverse Drug Reactions and Interactions in Croatia
por: Raguz Lucic, Nikola, et al.
Publicado: (2018)

Hepatocellular Carcinoma Occurrence and Recurrence in Hepatitis C-infected Patients Treated with Direct-acting Antivirals
por: Syed, Taseen, et al.
Publicado: (2018)

Preclinical Models and Promising Pharmacotherapeutic Strategies in Liver Fibrosis: An Update
por: Kolaric, Tea Omanovic, et al.
Publicado: (2023)

Therapeutic Perspectives of IL1 Family Members in Liver Diseases: An Update
por: Ćurčić, Ines Bilić, et al.
Publicado: (2022)

Noninvasive Fibrosis Assessment in Chronic Hepatitis C Infection: An Update
por: Bojanic, Kristina, et al.
Publicado: (2023)

Drug-induced Fatty Liver Disease: Pathogenesis and Treatment
por: Kolaric, Tea Omanovic, et al.
Publicado: (2021)

Biomarkers for Hepatocellular Carcinoma: From Origin to Clinical Diagnosis
por: Omar, Mona A., et al.
Publicado: (2023)

Management of Glycemia during Acute Aerobic and Resistance Training in Patients with Diabetes Type 1: A Croatian Pilot Study
por: Ivandic, Marul, et al.
Publicado: (2023)

Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: Biologically plausible or an epiphenomenon?
por: Butt, Amna Subhan, et al.
Publicado: (2018)

Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C
por: Kawagishi, Naoki, et al.
Publicado: (2023)

De novo hepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agents
por: Kuftinec, Gabriela, et al.
Publicado: (2018)

Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate
por: Kamal, Ahmed, et al.
Publicado: (2022)

Mechanistic-Based Classification of Endocytosis-Related Inhibitors: Does It Aid in Assigning Drugs against SARS-CoV-2?
por: Hessien, Mohamed, et al.
Publicado: (2023)

Direct-Acting Antiviral Drugs and Occurrence of Hepatocellular Carcinoma: Unjust or Oppressed
por: Hassany, Sahar M, et al.
Publicado: (2020)

Update on the Development of Anti-Viral Agents Against Hepatitis C
por: Macarthur, Kristin L., et al.
Publicado: (2013)

Direct-Acting Antiviral Therapy and Risk of Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C
por: Lee, Chang Hun, et al.
Publicado: (2021)

Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents
por: Kishta, Sara Sobhy, et al.
Publicado: (2017)

HCV Extrahepatic Manifestations
por: Kuna, Lucija, et al.
Publicado: (2019)

Impact of direct-acting antiviral therapy for hepatitis C–related hepatocellular carcinoma
por: Lin, Wei-Chen, et al.
Publicado: (2020)

Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma
por: Tajiri, Kazuto, et al.
Publicado: (2022)

Decreased risk of hepatocellular carcinoma recurrence with direct-acting antivirals compared with no treatment for hepatitis C: a meta-analysis
por: Lui, Felix H., et al.
Publicado: (2020)

Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C
por: Ahn, Young-Hwan, et al.
Publicado: (2021)

Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment
por: Ahn, Young-Hwan, et al.
Publicado: (2022)

The Complex Interplay Relationship between HCV Infection, Direct-Acting Antiviral Therapy, and Hepatocellular Carcinoma Occurrence
por: Cavalletto, Luisa, et al.
Publicado: (2023)

LIFESTYLE RISK FACTORS AND BONE MASS IN RECURRENT STONE-FORMING PATIENTS: A CROSS-SECTIONAL STUDY IN 144 SUBJECTS
por: Marić, Ivana, et al.
Publicado: (2019)

Circulating Exosomal miRNA Profiles Predict the Occurrence and Recurrence of Hepatocellular Carcinoma in Patients with Direct-Acting Antiviral-Induced Sustained Viral Response
por: Itami-Matsumoto, Saori, et al.
Publicado: (2019)

Multimodal Treatment of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antivirals
por: Mercan-Stanciu, Adriana, et al.
Publicado: (2022)

Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals
por: Leal, Cassia, et al.
Publicado: (2023)

Peptic Ulcer Disease: A Brief Review of Conventional Therapy and Herbal Treatment Options
por: Kuna, Lucija, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_de28emirbjlsgk8h26b0uv2hga